Welcome to our dedicated page for CalciMedica news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CalciMedica stock.
CalciMedica, Inc. develops calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The clinical-stage biopharmaceutical company’s lead product candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor based on zegocractin and is being studied across severe inflammatory conditions involving tissue cell injury.
Company news commonly covers financial results, clinical and preclinical updates, regulatory discussions, publications, and corporate developments. Recurring program topics include Auxora data in acute pancreatitis with systemic inflammatory response syndrome, severe COVID-19 pneumonia, and acute kidney injury, as well as preclinical work on CM5480 in pulmonary arterial hypertension.
CalciMedica (Nasdaq: CALC) announced publication in JCI Insight of preclinical data for its CRAC channel inhibitor CM5480, showing benefit in a monocrotaline (MCT) rat model of pulmonary arterial hypertension (PAH).
Key findings: daily CM5480 at 20 mg/kg reduced pulmonary neomuscularization, right ventricular systolic pressure (RVSP), pulmonary vascular resistance (PVR) and RV hypertrophy; CM5480 restored heart contraction, cardiac output and several disease‑linked gene and metabolic pathways. Combination therapy with ambrisentan or sildenafil produced greater improvements than either SOC agent alone. Authors include CalciMedica leaders and PAH researchers from Inserm and Université Paris‑Saclay.
The release links these results to CalciMedica's lead program Auxora and the ongoing Phase 2 KOURAGE trial in AKI, with data expected in 1H 2026.
CalciMedica (NASDAQ: CALC) presented preclinical data at ASN Kidney Week 2025 showing that three-day IV dosing of Auxora (16 mg/kg) in a rat ischemia/reperfusion AKI model reduced kidney Th‑17 cells by 64% versus placebo and lung Th‑17 cells by 59% (each p<0.05).
Auxora also decreased IL‑6–producing CD4 cells in lung by 69% (p<0.05), produced greater GFR recovery (p<0.01), lower serum creatinine (p<0.05) at 72 hours, and reduced tubular injury by >50% versus placebo. Findings support the mechanistic rationale for Auxora in severe AKI with acute hypoxemic respiratory failure and align with the ongoing Phase 2 KOURAGE trial targeting patients with elevated IL‑17.
CalciMedica (NASDAQ: CALC) announced a collaboration with Telperian to integrate Telperian's AI engine into analysis of completed Phase 2 clinical trial datasets for Auxora, including the CARPO (acute pancreatitis with SIRS) and CARDEA (severe COVID-19 pneumonia) trials.
Telperian will apply AI, biostatistics, subtyping, and historical-study emulations to refine target patient subgroups, efficacy endpoints, and to generate data-supported insights to support CalciMedica's regulatory discussions with the FDA for a final pivotal trial design in acute pancreatitis. Auxora is also being evaluated in the Phase 2 KOURAGE trial, with data expected in early 2026.
CalciMedica (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies, announced its participation in the upcoming H.C. Wainwright Global Investment Conference. CEO Rachel Leheny, Ph.D. will present on September 8, 2025, at 3:30 p.m. ET.
The presentation will be available via live webcast in the "IR Events and Presentations" section of CalciMedica's website, with a replay accessible for 90 days following the event.
CalciMedica (NASDAQ:CALC) reported Q2 2025 financial results and provided updates on its clinical programs. The company reported a net loss of $6.0 million ($0.40 per share), compared to $4.0 million in Q2 2024. Cash position stands at $18.0 million, expected to fund operations into mid-2026.
Key clinical developments include ongoing enrollment in the Phase 2 KOURAGE trial of Auxora™ for acute kidney injury (AKI) with respiratory failure, with data expected in early 2026. The company also held a productive initial FDA meeting regarding Auxora in acute pancreatitis (AP), with pivotal trial alignment anticipated by end of 2025.
R&D expenses decreased slightly to $4.1 million from $4.2 million year-over-year, while G&A expenses increased to $2.6 million from $2.4 million.
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies, announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. CEO Rachel Leheny, Ph.D. will engage in a fireside chat on July 14, 2025, at 2:00 p.m. ET.
The presentation will be accessible through a live webcast in the "IR Events and Presentations" section of CalciMedica's investor relations website, with a replay available for 90 days following the event.
CalciMedica (NASDAQ:CALC) announced the publication of a manuscript in the American Journal of Nephrology detailing the design and rationale of their Phase 2 KOURAGE trial for Auxora™ in acute kidney injury (AKI) with respiratory failure. The publication includes promising preclinical data and a post-hoc analysis from the CARDEA trial.
Key findings include: 62.7% relative reduction and 29.3% absolute reduction in mortality for Auxora versus placebo in AKI patients from the CARDEA trial. The drug showed significant benefits in preclinical models, increasing glomerular filtration rate and preventing mortality. The research addresses a critical medical need, as approximately 3.7 million patients are hospitalized with AKI annually in the U.S., with a 50% mortality rate for severe cases with respiratory failure.
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company, has announced its participation in two major medical conferences in May 2025. At Digestive Disease Week (DDW) 2025 in San Diego, CSO Kenneth A. Stauderman will present research on acute pancreatitis patients with SIRS and their volume distribution compared to healthy volunteers.
Additionally, Chief Medical Officer Sudarshan Hebbar will participate in the American Society of Nephrology (ASN) 3rd Acute Kidney Injury Conference in Leesburg, VA. Dr. Hebbar will deliver an oral presentation on AKI Clinical Trial Design and participate in a panel discussion on non-academic careers in science. The company, which focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses, will make the presentations available on their IR website.